Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2023)

Historic Return on Capital Employed for Candel Therapeutics (CADL) over the last 3 years, with Q3 2023 value amounting to 0.82%.

  • Candel Therapeutics' Return on Capital Employed fell 4100.0% to 0.82% in Q3 2023 from the same period last year, while for Sep 2023 it was 0.82%, marking a year-over-year decrease of 4100.0%. This contributed to the annual value of 0.45% for FY2022, which is 100.0% down from last year.
  • According to the latest figures from Q3 2023, Candel Therapeutics' Return on Capital Employed is 0.82%, which was down 4100.0% from 0.66% recorded in Q2 2023.
  • Candel Therapeutics' Return on Capital Employed's 5-year high stood at 0.29% during Q4 2021, with a 5-year trough of 0.82% in Q3 2023.
  • Moreover, its 3-year median value for Return on Capital Employed was 0.41% (2022), whereas its average is 0.48%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first changed by 0bps in 2022, then crashed by -4100bps in 2023.
  • Quarter analysis of 3 years shows Candel Therapeutics' Return on Capital Employed stood at 0.29% in 2021, then plummeted by -55bps to 0.46% in 2022, then crashed by -79bps to 0.82% in 2023.
  • Its Return on Capital Employed stands at 0.82% for Q3 2023, versus 0.66% for Q2 2023 and 0.53% for Q1 2023.